HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Elevated monoamine oxidase a binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms.

Abstract
Inadequate treatment response occurs in approximately 40% of major depressive episodes (MDEs), and one approach to solve this is careful matching of treatment to the specific pathologies of MDE. One such biological abnormality is elevated monoamine oxidase A (MAO-A) levels, which occurs in the prefrontal and anterior cingulate cortex (PFC and ACC) during MDE; however, the subtypes for which this abnormality is most prominent are unknown. We hypothesized that MAO-A levels in the PFC and ACC are most elevated in MDE with greater severity and reversed neurovegetative symptoms (hypersomnia and either hyperphagia or weight gain). MAO-A VT (an index of MAO-A density) was measured using [(11)C]harmine positron emission tomography (PET) in 42 subjects with MDEs secondary to major depressive disorder and 37 healthy controls. The effect of severity and reversed neurovegetative symptoms on MAO-A VT in the PFC and ACC was analyzed using a multivariate analysis of variance (MANOVA). Greater severity and reversed neurovegetative symptoms were associated with elevated MAO-A VT in the PFC and ACC (MANOVA, severity: F(2,38)=5.44, p=0.008; reversed neurovegetative symptoms: F(2,38)=5.13, p=0.01). Increased MAO-A level, when greater severity and reversed neurovegetative symptoms are present, may explain the association of these clinical features with a preferential response to MAO inhibitors, which is especially well-evidenced for reversed neurovegetative symptoms in MDE. As MAO-A creates oxidative stress, facilitates apoptosis, and metabolizes monoamines, therapeutics opposing these processes are predicted to best treat MDE with greater severity and reversed neurovegetative symptoms.
AuthorsLina Chiuccariello, Sylvain Houle, Laura Miler, Robert G Cooke, Pablo M Rusjan, Grazyna Rajkowska, Robert D Levitan, Stephen J Kish, Nathan J Kolla, Xiaoming Ou, Alan A Wilson, Jeffrey H Meyer
JournalNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (Neuropsychopharmacology) Vol. 39 Issue 4 Pg. 973-80 (Mar 2014) ISSN: 1740-634X [Electronic] England
PMID24154665 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Carbon Radioisotopes
  • Monoamine Oxidase Inhibitors
  • Harmine
  • Monoamine Oxidase
Topics
  • Adult
  • Carbon Radioisotopes (pharmacokinetics)
  • Cerebral Cortex (diagnostic imaging, drug effects)
  • Depressive Disorder, Major (classification, complications, diagnostic imaging)
  • Disorders of Excessive Somnolence (diagnostic imaging, etiology)
  • Female
  • Harmine (pharmacokinetics)
  • Humans
  • Hyperphagia (diagnostic imaging, etiology)
  • Magnetic Resonance Imaging
  • Male
  • Monoamine Oxidase (metabolism)
  • Monoamine Oxidase Inhibitors (pharmacokinetics)
  • Positron-Emission Tomography
  • Protein Binding (drug effects, physiology)
  • Psychiatric Status Rating Scales
  • Severity of Illness Index
  • Statistics, Nonparametric
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: